PeptideInjectablePeptideSecretagogueGHRPGhrelin receptor agonist

GHRP-2

Also known as GHRP-2 · Pralmorelin · KP-102

Written by enwyReviewed 4 Aug 20262 sources0 comments

GHRP-2 (pralmorelin) is a second-generation growth-hormone-releasing peptide and ghrelin-receptor agonist, more potent at releasing GH than GHRP-6 and with somewhat less appetite stimulation. It is approved in Japan as a diagnostic agent for GH secretion, giving it more human data than most secretagogues. Non-medical physique use remains anecdotal.

01 Overview

GHRP-2 potently stimulates a GH pulse via the ghrelin receptor. It still increases appetite and modestly raises cortisol and prolactin, but generally less hunger than GHRP-6 at comparable GH release. Its use as an approved diagnostic (pralmorelin) in Japan provides validated human pharmacology.

It is commonly paired with a GHRH analogue in non-medical use for synergistic GH release. Efficacy for body composition in healthy adults is not established by controlled trials.

02 Mechanism

Potent agonist of the growth-hormone secretagogue receptor (GHS-R1a, ghrelin receptor) that evokes a strong GH pulse, with lesser appetite stimulation than GHRP-6 and modest cortisol/prolactin effects.

03 Dosing

Tier	Dose	Route	Notes
Anecdotal (non-medical)	100–300 mcg	SubQ	~100-300 mcg per injection, often 1-3x/day; frequently combined with a GHRH analogue.

04 Effects

Effect	Magnitude	Evidence
Strong GH releasePotent GH-releasing effect validated in human diagnostic use.		Clinical
Appetite stimulationGhrelin-mediated hunger, generally milder than GHRP-6.		Clinical
Fat loss and recoveryReported body-composition and recovery benefits; not established in physique trials.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Appetite increaseIncreased hunger after dosing, less pronounced than GHRP-6.	Mild	Common	Clinical
Raised cortisol and prolactinModest ACTH/cortisol and prolactin elevation at higher doses.	Moderate	Uncommon; less than GHRP-6/hexarelin	Clinical
Water retention / injection-site reactionsFluid retention and local injection reactions.	Mild	Common	Anecdotal

06 Legal status

United States

Research chemical; not FDA-approved for human use

WADA-prohibited; not lawfully marketed for human consumption in the US. · as of Jan 2026

Approved diagnostic agent (pralmorelin)

as of Jan 2026

07 References

GHRP-2 (pralmorelin) as a GH-secretion testPubMed

Comparative pharmacology of GH-releasing peptidesPubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.